Serif Biomedicines, a biotech developing DNA-based medicines, launched with $50 million in backing from Flagship Pioneering, the life sciences firm announced Tuesday.
The big picture: Serif is Flagship's latest bet on next-generation genetic medicines, a fast-growing but challenging area in biotech.
